iTeos Therapeutics (ITOS) Price & Analysis

Compare

192 Followers

ITOS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.80 - $18.13

Previous CloseN/A

Volume59.28K

Average Volume (3M)1.83M

Market Cap

$384.27M

Enterprise Value$414.20M

Total Cash (Recent Filing)$520.37M

Total Debt (Recent Filing)$5.05M

Price to Earnings (P/E)―

Beta1.72

Next Earnings

Aug 07, 2025

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding38,273,796

10 Day Avg. Volume946,046

30 Day Avg. Volume1,825,517

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)1.05

Price to Sales (P/S)0.00

P/FCF Ratio-6.19

Enterprise Value/Market Cap1.08

Enterprise Value/Revenue3.53

Enterprise Value/Gross Profit11.94

Enterprise Value/Ebitda-0.72

Forecast

1Y Price Target

$11.00

Price Target Upside9.78% Upside

Rating ConsensusHold

Number of Analyst Covering6

iTeos Therapeutics News

PremiumCompany Announcements

iTeos Therapeutics Holds Annual Stockholders Meeting

11d ago

ITOS

PremiumCompany Announcements

Tim Van Hauwermeiren Resigns from iTeos Board

22d ago

ITOS

PremiumRatings

iTeos Therapeutics: Strategic Wind Down to Maximize Shareholder Value Amid Limited Pipeline Prospects

29d ago

ITOS

PremiumThe Fly

iTeos Therapeutics downgraded to Equal Weight at Wells Fargo on wind down

1M ago

ITOS

PremiumThe Fly

iTeos Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

1M ago

ITOS

PremiumMarket News

iTeos Therapeutics Stock (ITOS) Booms 24% as it Winds Down and Sells Cancer Treatments

1M ago

ITOS

PremiumThe Fly

iTeos Therapeutics downgraded to Neutral at Wedbush after wind down decision

1M ago

ITOS

PremiumThe Fly

iTeos Therapeutics downgraded to Neutral from Outperform at Wedbush

1M ago

ITOS

See All ITOS News

See All News >

Bulls Say, Bears Say

Bulls Say

Cash PositionITeos has a strong cash position of $624 million and a lean research and development spending outlook, attracting activist-leaning investors.

Financial PerformanceBy taking the decision to wind down operations, iTeos Therapeutics is leveraging its strong cash position to return as much value as possible to shareholders.

Stock MovementInvestors reacted positively to the news of belrestotug’s termination, with the stock showing an increase, likely due to the announcement of a strategic review to maximize shareholder value.

Bears Say

Clinical TrialsThe decision to discontinue the Fc-competent anti-TIGIT, belrestotug, was made after studies failed to show clinically meaningful improvements over anti-PD-1 monotherapy.

Rating And StrategyThe rating on ITOS is lowered to Neutral without a price target due to uncertainties regarding iTeos’ pipeline development and business strategies going forward.

UncertaintyThere is low confidence that any early-stage immuno-oncology asset will add value for iTeos in the next year, as the investor bar for excitement is high.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

23.82% Insiders

13.46% Mutual Funds

<0.01% Other Institutional Investors

52.95% Public Companies and Individual Investors

Detailed Ownership Overview >

ITOS FAQ

What was iTeos Therapeutics’s price range in the past 12 months?

iTeos Therapeutics lowest stock price was $4.80 and its highest was $18.13 in the past 12 months.

What is iTeos Therapeutics’s market cap?

iTeos Therapeutics’s market cap is $384.27M.

When is iTeos Therapeutics’s upcoming earnings report date?

iTeos Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 40 days.

How were iTeos Therapeutics’s earnings last quarter?

iTeos Therapeutics released its earnings results on Apr 28, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.95 by $0.15.

Is iTeos Therapeutics overvalued?

According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does iTeos Therapeutics pay dividends?

iTeos Therapeutics does not currently pay dividends.

What is iTeos Therapeutics’s EPS estimate?

iTeos Therapeutics’s EPS estimate is -0.89.

How many shares outstanding does iTeos Therapeutics have?

iTeos Therapeutics has 38,273,796 shares outstanding.

What happened to iTeos Therapeutics’s price movement after its last earnings report?

iTeos Therapeutics reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.95. Following the earnings report the stock price went down -3.112%.

Which hedge fund is a major shareholder of iTeos Therapeutics?

Currently, no hedge funds are holding shares in ITOS

iTeos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-23.68%

Trailing 12-Months

Asset Growth

4.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

iTeos Therapeutics

iTeos Therapeutics (ITOS) is a biotechnology company dedicated to the discovery and development of novel cancer immunotherapies. The company operates primarily in the pharmaceutical and biotechnology sectors, focusing on creating innovative treatments that harness the body's immune system to fight cancer. Its core products are centered around immuno-oncology drug candidates designed to target specific pathways involved in immune resistance and tumor growth.

ITOS Stock 12 Month Forecast

Average Price Target

$11.00

▲(9.78%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,7.846153846153846,8.192307692307692,8.538461538461538,8.884615384615385,9.23076923076923,9.576923076923077,9.923076923076923,10.26923076923077,10.615384615384615,10.961538461538462,11.307692307692307,11.653846153846153,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,7.769230769230769,8.038461538461538,8.307692307692308,8.576923076923077,8.846153846153847,9.115384615384615,9.384615384615385,9.653846153846153,9.923076923076923,10.192307692307692,10.461538461538462,10.73076923076923,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.5,7.538461538461538,7.576923076923077,7.615384615384615,7.653846153846154,7.6923076923076925,7.730769230769231,7.769230769230769,7.8076923076923075,7.846153846153846,7.884615384615385,7.923076923076923,7.961538461538462,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.81,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.78,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >